Effects of concomitant methotrexate and predictors of remission in Janus kinase inhibitor therapy for rheumatoid arthritis
Authors' conclusion
Concomitant MTX provided potential advantages in terms of early disease control in JAK inhibitor therapy for RA, particularly in patients with active disease.
Study context
- Population
- Rheumatoid arthritis (RA) patients treated with JAKi681 treatment courses
- Participants
- 569 patients
- Exposure
- Concomitant methotrexate (MTX) vs no concomitant MTX during JAKi therapy
- Outcome
- CDAI remission
- Follow-up
- 24 weeks
Methodological detailsinverse probability of treatment weighting, multivariate logistic regression
- Inverse probability of treatment weighting
- Multivariate logistic regression
Main finding
As reported in the abstract
Radiographic damage, OR
0.48
95% CI 0.30–0.77
Prior b/tsDMARD use, OR
0.57
95% CI 0.36–0.90
GC use, OR
0.65
95% CI 0.43–0.98
Baseline Clinical Disease Activity Index (CDAI) score, OR per 1 point
0.96
95% CI 0.94–0.98
Observational data: associations, not effects.
Further findings
Proportion achieving CDAI remission (all patients)
- Baseline
- 5%
- 4 weeks
- 22%
- 12 weeks
- 31%
- 24 weeks
- 36%
- Estimated mean CDAI 17.6 at baseline, significantly decreased after 4 weeks
CDAI remission, MTX (+) vs MTX (-) · 12 weeks
- Significantly higher proportion achieving CDAI remission with MTX (+)
- After inverse probability of treatment weighting adjustment
CDAI remission, MTX (+) vs MTX (-) · 24 weeks
- No significant difference
CDAI remission, MTX (+) vs MTX (-), moderate to high disease activity (subgroup)
- Difference evident among patients with moderate to high disease activity
Original publication
Composed by AI from the published abstract and checked against it. How Briefs are made →